Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
In a study trial, Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in weight loss efficacy. The study was conducted by ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Viking has a strong GLP-1 agonist candidate that may win approval by 2027, and makes the company a target for M&A. Read the ...
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.